Table 1.
The effects of different clinicopathological factors on MYL9 gene expression and clinical prognosis were determined by Kaplan–Meier plotter
| Clinicopathological characteristics | Overall survival (n = 875) | postprogression survival (n = 498) | ||||
|---|---|---|---|---|---|---|
| N | Hazard ratio | p value | N | Hazard ratio | p value | |
| Sex | ||||||
| Male | 544 | 2.96 (2.25–3.9) | 6.60E–16 | 348 | 3.83 (2.86–5.13) | 1.00E–16 |
| Female | 236 | 2.65 (1.77–3.97) | 8.30E–07 | 149 | 3.5 (2.22–5.53) | 1.30E–08 |
| Stage | ||||||
| I | 67 | 3.99 (1.27–12.56) | .011 | 31 | ‐ | ‐ |
| II | 140 | 2.3 (1.26–4.19) | .0052 | 105 | 2.75 (1.42–5.33) | .0018 |
| III | 305 | 2.7 (1.82–3.99) | 2.50E–07 | 142 | 4.2 (2.54–6.95) | 1.90E–09 |
| IV | 148 | 1.87 (1.21–2.9) | .0043 | 104 | 2 (1.26–3.18) | .0028 |
| Stage T | ||||||
| 2 | 241 | 2.11 (1.37– 3.23) | .00046 | 196 | 3.01 (1.92–4.72) | 4.70E–07 |
| 3 | 204 | 2.06 (1.42–3) | .00011 | 150 | 2.62 (1.72–3.98) | 3.00E–06 |
| 4 | 38 | 3.48 (1.36−8.93) | .0061 | 29 | 1.89 (0.67–5.32) | .22 |
| Stage N | ||||||
| 0 | 74 | 3.09 (1.19–7.98) | .015 | 41 | 7.85 (2.09–29.43) | .00034 |
| 1 | 225 | 3.45 (2.22–5.35) | 4.10E–09 | 169 | 5.25 (3.23–8.55) | 1.60E–13 |
| 2 | 121 | 3.1 (1.91–5.04) | 1.70E–06 | 105 | 3.26 (1.94–5.47) | 2.70E–06 |
| 3 | 76 | 2.15 (1.23–3.78) | .0064 | 63 | 2.27 (1.24–4.15) | .0061 |
| 1 + 2 + 3 | 422 | 2.73 (2.06–3.63) | 5.00E–13 | 337 | 3.37 (2.5–4.54) | 1.00E–16 |
| Stage M | ||||||
| 0 | 444 | 2.5 (1.87–3.33) | 1.00E–10 | 342 | 3.81 (2.78–5.22) | 1.00E–16 |
| 1 | 56 | 2.21 (1.2–4.07) | .0095 | 36 | 3.38 (1.48–7.68) | .0024 |
| Lauren classification | ||||||
| Intestinal | 320 | 3.03 (2.14–4.28) | 5.10E–11 | 192 | 4.49 (2.94–6.84) | 2.80E–14 |
| Diffuse | 241 | 2.39 (1.67–3.41) | 8.70E–07 | 176 | 2.69 (1.8–4.03) | 5.10E–07 |
| Mixed | 32 | 3.79 (1.2–11.97) | 1.50E–02 | 16 | ‐ | ‐ |
| Differentiation | ||||||
| Poor | 165 | 1.63 (0.95–2.79) | .071 | 49 | 1.5 (0.73–3.06) | .27 |
| Moderate | 67 | 1.77 (0.92–3.39) | .081 | 24 | 0.62 (0.22– 1.78) | .37 |
| Well | 32 | 6.46 (2.13−19.56) | .00018 | 0 | ‐ | ‐ |
| HER2 status | ||||||
| HER2 negative | 532 | 2.59 (2–3.35) | 6.60E–14 | 334 | 3.38 (2.5– 4.57) | 1.00E–16 |
| HER2 positive | 343 | 1.81 (1.3–2.52) | 4.00E–04 | 164 | 4 (2.51–6.36) | 3.90E–10 |
Abbreviation: MYL9, myosin light chain 9.